Mesothelioma and Asbestos Claimant Acquisition: 2026 Intake Guide

Asbestos litigation is the oldest mass tort still running. It covers mesothelioma and asbestos-related lung cancer claims against solvent defendants in state court, claims against more than 60 bankruptcy trusts, and a talc front against Johnson & Johnson that produced some of the largest single-plaintiff verdicts of 2025.

Intake teams should care right now because filings have climbed for three straight years, talc allegations are pulling in claimants who never worked an industrial job, and the claimant population has the shortest life expectancy of any tort you will screen. The firm that gets a clean, verified case in the door first usually keeps it.

Where the litigation stands (September 2026)

There is no active MDL for asbestos personal injury. The action is in state courts. KCIC's 2025 year in review, reported in May 2026, found that mesothelioma made up 48 percent of asbestos filings and lung cancer another 40 percent, with filings rising for the third consecutive year to pre-pandemic levels. Madison County and St. Clair County in Illinois remained the leading venues. Philadelphia filings rose about 40 percent, New York City about 25 percent, Middlesex County, New Jersey climbed, and Richland County, South Carolina entered the top 15 for the first time.

The second pillar is the trust system. Companies that went bankrupt under asbestos liabilities, Johns-Manville among the best known, funded trusts to pay future claimants. As of 2026, more than 60 active trusts hold an estimated $30 billion or more. Each trust pays a scheduled value per disease level, discounted by a payment percentage that runs from roughly 1 percent to 60 percent depending on solvency. Claims go through expedited review (faster, fixed amounts) or individual review (slower, potentially higher). Most mesothelioma claimants file with 10 or more trusts, in parallel with the lawsuit against solvent defendants.

The third pillar is talc. Johnson & Johnson's cosmetic talc is alleged to have been contaminated with asbestos, and mesothelioma plaintiffs (as distinct from ovarian cancer plaintiffs) are trying those cases individually in state courts. J&J's third bankruptcy attempt, through the Red River Talc subsidiary, was dismissed on March 31, 2025 by Judge Christopher Lopez of the U.S. Bankruptcy Court in Houston, who found the pre-filing vote flawed and rushed. J&J has since said it will litigate the remaining cases one by one. The results were large: a $966 million Los Angeles verdict in October 2025 in the Mae Moore case, a reported $1.5 billion Baltimore verdict in December 2025 for peritoneal mesothelioma plaintiff Cherie Craft, and a $32 million Los Angeles verdict in June 2026 in the Lozano wrongful death case. J&J is appealing. Ovarian cancer claims sit in MDL 2738 before Judge Michael A. Shipp in the District of New Jersey, where a proposed $5.5 billion settlement was reported in late July 2026; it does not resolve the mesothelioma docket. KCIC found talc-only asbestos filings grew 47 percent in 2025.

What a qualified claimant looks like

The core of a signable case has not changed in decades: a confirmed diagnosis plus a provable exposure. Occupational claimants still dominate: shipyard workers, Navy veterans, pipefitters, insulators, electricians, mechanics, refinery and plant workers. Veterans account for roughly a third of mesothelioma diagnoses, and Navy veterans are the largest share. Take-home claimants, usually spouses and children who laundered work clothes, are an established category. Talc claimants are a third population: long-term users of cosmetic talc, often women with no industrial history.

Firms are signing claimants who meet the following:

• A diagnosis of mesothelioma (pleural or peritoneal) confirmed by pathology, or asbestos-related lung cancer with supporting evidence such as pleural plaques, asbestosis or a heavy documented exposure history. Smoking does not disqualify a lung cancer claimant, but it raises the bar on exposure proof.
• An exposure history tied to specific job sites, employers, ships or products, with approximate dates. For veterans, a DD-214, ship assignments and occupational rating usually suffice.
• For take-home claims, a household member with documented occupational exposure and an account of how fibers reached the home.
• For talc claims, a credible account of regular, long-term use and the brand involved.
• A living claimant, or a personal representative for a wrongful death claim, within the statute of limitations.

Limitations periods run from diagnosis under the discovery rule in most states and range from one year (California, Kentucky, Louisiana and Tennessee) to six. Wrongful death deadlines run from the date of death and are often shorter. Venue is the firm's call, but a screener should capture every state of residence, employment and exposure, because those facts decide where the case can be filed.

Where intake goes wrong on this tort

The first and most expensive failure is the unconfirmed diagnosis. "Lung cancer" is not "asbestos-related lung cancer," and a CT finding of pleural effusion is not mesothelioma. Screeners who accept a self-reported diagnosis without asking who made it and whether a biopsy was performed send the firm cases that collapse on the first records request. The reverse error also happens: a caller with confirmed mesothelioma who says "I never worked around asbestos" is dismissed, when a few more questions would have surfaced a father who came home from the shipyard in dusty coveralls, or 30 years of daily talc use.

The second failure is vague exposure. A claimant who says "construction" and cannot name an employer, a site, a decade or a product is not yet a case. Product identification decides the case against solvent defendants, and each trust requires it separately. Good intake gets the work history in order, including union locals, coworkers who might testify, and the veteran's ship list. It does not coach the answers. Coached narratives, where every caller from one source names the same three products, are a pattern defense counsel and trust auditors watch for.

The third failure is duplication. Patients and families call multiple firms within days of a diagnosis. A claimant who already signed elsewhere, or whose trust claims were filed by prior counsel, generates a fee dispute rather than a case. The fourth is geography: a claimant living in one state, exposed in a second and treated in a third has to reach a firm that can actually file, and a screener who captures only the current address cannot route that.

What acquisition looks like

Mesothelioma has been one of the most expensive keyword categories in legal advertising for more than a decade. KCIC noted in 2015 that "mesothelioma lawyer" was among Google's priciest search terms, and July 2026 keyword data still places mesothelioma attorney and law firm terms among the most expensive in the legal category. The pool of new diagnoses each year is small, the case values are large, and every firm that handles the work bids on the same handful of phrases.

Acquisition for this tort therefore looks different from a consumer product tort. Search captures people actively looking for a lawyer, but the highest-intent moments happen offline: in oncology waiting rooms, veteran service organizations, union halls and the household of a patient who was just told the word "mesothelioma." Digital campaigns that work are built around the diagnosis rather than the exposure, because the family often knows the diagnosis before it knows the exposure history. Veteran creative, take-home creative aimed at adult children of tradesmen, and talc creative aimed at women with a mesothelioma diagnosis each reach a population the generic "asbestos exposure" ad misses.

What drives cost is scarcity of true positives and the noise around them. Lung cancer inquiries far outnumber mesothelioma inquiries, and most lung cancer callers have no provable asbestos exposure. Talc creative pulls in ovarian cancer callers who belong in a different docket. And because the claimant is often gravely ill, the caller is frequently a spouse or adult child who cannot answer exposure questions on the first call. Each factor raises the cost of a verified case relative to a raw inquiry.

How Slingshot screens for this tort

Direct opt-in matters more on this tort than most, because the caller is often a family member acting for a patient. We document who consented and in what capacity, with TCPA consent recorded, and confirm the patient or personal representative agrees to the contact before the prospect goes to a firm. Identity verification confirms the claimant is a real person matching the diagnosis and, for wrongful death, that the caller has standing to act.

Document authentication is where mesothelioma intake is won or lost. We ask for the pathology report or the treating physician's diagnosis, not a description of it, and we capture the exposure history in the claimant's own words with employers, sites, ships, products and dates. We flag prior representation or prior trust filings before the file moves. Post-signature engagement keeps the claimant reachable through treatment, because a claimant who cannot be found for a records authorization or a deposition date is a case that may stall for good.

Frequently asked questions

Does a claimant need to know which products exposed them before signing?

No, and most do not. A claimant needs a diagnosis and a work or household history detailed enough for the firm to match against its records of which asbestos-containing products were used at which facilities and on which ships. The screener's job is to capture the raw history, not to supply product names.

Can an asbestos lung cancer claimant with a smoking history still qualify?

Guidance published by plaintiff firms in 2026 is consistent: smoking does not disqualify a lung cancer claimant, because asbestos and smoking together multiply risk. The practical effect is that exposure proof has to be stronger, and firms look for corroborating findings such as pleural plaques or asbestosis, or a heavy documented occupational exposure.

How fast does a mesothelioma case need to move?

Faster than any other tort. Pleural mesothelioma patients who receive treatment survive a reported 12 to 21 months on average, and limitations periods run from diagnosis, as short as one year in several states. Firms want the claimant deposed while they can still testify. A prospect delivered weeks after first contact rather than days may already be a wrongful death case with a different deadline and plaintiff.

Sources

This article is published by Slingshot Legal Support, a legal marketing and claimant acquisition company. It is not legal advice and does not create an attorney-client relationship. Litigation status is described as publicly reported as of the publication date and changes frequently.